Gonadotropin preparations

(Redirected from Corifollitropin alfa)
Jump to: navigation, search

WikiDoc Resources for Gonadotropin preparations


Most recent articles on Gonadotropin preparations

Most cited articles on Gonadotropin preparations

Review articles on Gonadotropin preparations

Articles on Gonadotropin preparations in N Eng J Med, Lancet, BMJ


Powerpoint slides on Gonadotropin preparations

Images of Gonadotropin preparations

Photos of Gonadotropin preparations

Podcasts & MP3s on Gonadotropin preparations

Videos on Gonadotropin preparations

Evidence Based Medicine

Cochrane Collaboration on Gonadotropin preparations

Bandolier on Gonadotropin preparations

TRIP on Gonadotropin preparations

Clinical Trials

Ongoing Trials on Gonadotropin preparations at Clinical Trials.gov

Trial results on Gonadotropin preparations

Clinical Trials on Gonadotropin preparations at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gonadotropin preparations

NICE Guidance on Gonadotropin preparations


FDA on Gonadotropin preparations

CDC on Gonadotropin preparations


Books on Gonadotropin preparations


Gonadotropin preparations in the news

Be alerted to news on Gonadotropin preparations

News trends on Gonadotropin preparations


Blogs on Gonadotropin preparations


Definitions of Gonadotropin preparations

Patient Resources / Community

Patient resources on Gonadotropin preparations

Discussion groups on Gonadotropin preparations

Patient Handouts on Gonadotropin preparations

Directions to Hospitals Treating Gonadotropin preparations

Risk calculators and risk factors for Gonadotropin preparations

Healthcare Provider Resources

Symptoms of Gonadotropin preparations

Causes & Risk Factors for Gonadotropin preparations

Diagnostic studies for Gonadotropin preparations

Treatment of Gonadotropin preparations

Continuing Medical Education (CME)

CME Programs on Gonadotropin preparations


Gonadotropin preparations en Espanol

Gonadotropin preparations en Francais


Gonadotropin preparations in the Marketplace

Patents on Gonadotropin preparations

Experimental / Informatics

List of terms related to Gonadotropin preparations

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Gonadotropin preparations are drugs that mimic the physiological effects of gonadotropins, used therapeutically mainly as fertility medication for ovarian hyperstimulation and reversal of anovulation. For example, the so-called menotropins consist of LH and FSH extracted from human urine from menopausal women.[1] There are also recombinant variants.

FSH and LH preparations

hMG (human Menopausal Gonadotrophins), FSH and LH prepared from human urine collected from postmenopausal women. First extracted in 1953.[2] Injected intra-muscularily (IM) or subcutaneously (SC).


menotropins for injections, USP


  • Menopur, 5 mL vials containing 75 IU FSH and 75 IU LH.
  • Repronex, vials containing either 75 IU FSH and 75 IU LH, or 150 IU FSH and 150 IU LH.

The more common side effects of preparations containing FSH and LH are:[3]

FSH preparations

Preparations of follicle-stimulating hormone (FSH) mainly include those derived from the urine of menopausal women, as well as recombinant preparations. The recombinant preparations are more pure and more easily administered, but they are more expensive. The urinary preparations are equally effective and less expensive, but are not as convenient to administer as they are available in vials versus injection pens. One study reported that users of the purified urinary FSH preparation Bravelle experienced less injection site pain compared to the recombinant preparation Follistim.[4]

Urinary preparations

Purified urinary FSH (75 IU FSH and ≤ 2 IU of LH)
urofollitropin for injection, purified.
  • Bravelle, U.S., (≤ 2 IU LH)
  • Metrodin, U.S. and Canada, (≤ 1 IU LH)
  • Fertinorm Hp, (Canada)
Highly purified urinary FSH (75 IU FSH and ≤ 0.1 IU LH/1000 IU FSH)
urofollitropin for injection, (highly) purified.
typically 75 - 300, but as high as 600 IU / day
Fertinex (≤ 0.1 IU LH/1000 IU FSH)

Recombinant preparations

Follitropin alfa
Follitropin alfa injection
Follitropin beta
follitropin beta injection
  • Follistim
  • Puregon

The package insert for Gonal-F states that based on physio-chemical tests and bioassays that follitropin beta and follitropin alfa are indistinguishable. Two studies showed no difference.[5][6] However, a more recent study showed there is may be a slight clinical difference, with the alfa form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels.[7]

The package insert for Puregon states that structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (hFSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural hFSH. However, these small differences do not affect the bioactivity compared to natural hFSH.

Side effects of FSH preparations

Side effects of FSH preparations include:[8]

  • Local irritation at the injection site
  • Feeling of fullness, bloating, and tenderness in the lower abdomen due to increasing size of the ovaries.
  • Mood swings
  • Fatigue

FSH Analogs

Corifollitropin alfa

Merck received approval on February 15, 2010 from the European Commission for ELONVA (corifollitropin alfa) a long lasting single injection fusion protein lacking LH activity. Only one injection is required for the first seven days, replacing the first seven daily injections of conventional FSH. Initial results demonstrates similar pregnancy rates as daily recombinant FSH injections.[9][10]

LH (Luteinizing hormone) preparations

Prepared from recombinant DNA.

lutropin alfa for injection

hCG (human Chorionic Gonadotropin) preparations

Used to induce final maturation of follicle and subsequent ovulation. Also used for luteal phase support. Typically a single injection of 10,000 international units is used to induce ovulation. Recent data has shown that subcutaneous injection works as well as intramuscular injection, however this form of administration is not FDA approved.[11]

Urinary preparations

Derived from the urine of pregnant women.

(human) chorionic gonadotropin for injection, USP
  • Pregnyl (Merck/Schering-Plough)
  • Follutein
  • Profasi
  • Novarel

Recombinant preparations

choriogonadotropin alfa for injection (recombinant human Chorionic Gonadotropin, r-hCG).


  1. Menotropins at the US National Library of Medicine Medical Subject Headings (MeSH)
  2. Ghumman, Surveen, 2006. Step by Step Ovulation Induction. Anshan Ltd, Kent, United Kingdom. ISBN 1-904798-96-9. Page 44.
  3. Follicle Stimulating Hormone and Luteinizing Hormone (Intramuscular Route, Subcutaneous Route) Side effects. From Mayo Clinic. Last updated: Nov. 1, 2011
  4. Dickey RP, Thornton M, Nichols J, Marshall DC, Fein SH, Nardi RV. Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta for in vitro fertilization: a prospective, randomized study. Fertility and Sterility 2002 Jun;77(6): 1202-8.
  5. Peter Brinsden, Fidelis Akagbosu, Lisa M Gibbons, Susan Lancaster, Dominique Gourdon, Patrick Engrand, Ernest Loumaye, 2000. "A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer." Fertility and sterility, 73(1): 114-116.
  6. R. Stan Williams, et al., 2003. "Pregnancy rates in varying age groups after in vitro fertilization: a comparison of follitropin alfa (Gonal F) and follitropin beta (Follistim)." American Journal of Obstetrics and Gynecology, 189(2):342-346.
  7. Orvieto R, Nahum R, Rabinson J, Ashkenazi J, Anteby EY, Meltcer S., 2009. "Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?" Fertility and Sterility 2009 Apr;91(4 Suppl):1522-5. Epub 2008 Oct 11. PMID 18851846
  8. Pharmacy FAQ from Regional Fertility Program, Cambrian Wellness Centre. Retrieved December 2013
  9. N. P. Koper, R. Boostanfar, P. Devroey, B. C. Fauser, P. C. IJzerman-Boon, B. M. J. L. Mannaerts. Global ClinicalDevelopment, Organon, Part of Schering-Plough Corporation, Oss, Netherlands; Huntington Reproductive Center, Tarzana, CA; Center of Reproductive Medicine, Dutch-speaking Free University, Brussels, Belgium; University Medical Center Utrecht, Utrecht, Netherlands; Biometrics, NV Organon, Part of Schering-Plough Corporation, Oss, Netherlands. "Corifollitropin alfa demonstrates similar pregnancy rates as compared to daily recombinant FSH treatment in a controlled ovarian stimulation regimen for IVF/ICSI." Fertility and Sterility, 90:page S75.
  10. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC, 2009. "A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol." Human Reproduction, 2009, August 14, [Epub ahead of print]. PMID 19684043.
  11. http://www.washivf.com/GWIVF-GWIVF_Content_C-Index_Page_Template_1143644788329.html

Template:Gonadotropins and GnRH